Rx Product News (June 2017)

ASN002, ASN003, AND ASN004

MARKETED BY: Asana BioSciences

INDICATION: Asana BioSciences presented preclinical data regarding 3 of its lead molecules: ASN002 (SYK/JAK inhibitor), ASN003 (BRAF/PI3K inhibitor), and ASN004 (5T4-targeted antibody drug conjugate). ASN002 is being evaluated in phase 1 and 2 clinical studies in patients with lymphomas, ASN003 is currently in phase 1 clinical development in patients with advanced solid tumors, and ASN004 is currently in preclinical development for tumor regressions.

FOR MORE INFORMATION: asanabiosciences.com

ZEJULA

MARKETED BY: Tesaro

INDICATION: The FDA has approved Zejula (niraparib) for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

DOSAGE FORM: Capsules: 100 mg

FOR MORE INFORMATION: tesarobio.com

XADAGO

MARKETED BY: Newron Pharmaceuticals

INDICATION: The FDA has approved Xadago (safinamide) as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa and experiencing “off” episodes.

DOSAGE FORM: Tablets: 50 and 100 mg

FOR MORE INFORMATION: newron.com

INGREZZA

MARKETED BY: Neurocrine Biosciences

INDICATION: The FDA has approved Ingrezza (valbenazine) as the first drug indicated to treat adults with tardive dyskinesia.

DOSAGE FORM: Capsules: 40 mg

FOR MORE INFORMATION: Neurocrine.com